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Abstract 25 
Entry of the enveloped Rift Valley fever virus (RVFV) into its host cell is mediated by the viral 26 
glycoproteins Gn and Gc. We investigated the RVFV entry process and its pH-dependent activation 27 
mechanism in particular using our recently developed nonspreading RVFV particle system. Entry of 28 
the virus into the host cell was efficiently inhibited by lysosomotropic agents that prevent endosomal 29 
acidification and by compounds that interfere with dynamin- and clathrin-dependent endocytosis. 30 
Exposure of plasma membrane-bound virions to an acidic pH (<pH 6) equivalent to the pH of late 31 
endo-lysosomal compartments allowed the virus to bypass the endosomal route of infection. Acid 32 
exposure of virions in the absence of target membranes triggered the class II-like Gc fusion protein to 33 
form extremely stable oligomers, resistant to SDS- and temperature-dissociation, and concomitantly 34 
compromised virus infectivity. By targeted mutagenesis of conserved histidines in Gn and Gc, we 35 
demonstrate that mutation of a single histidine (H857) in Gc completely abrogates virus entry as well 36 
as acid-induced Gc oligomerization. In conclusion, our data suggest that after endocytic uptake, RVFV 37 
traffics to the acidic late endo-lysosomal compartments where histidine protonation drives the 38 
reorganization of the Gc fusion protein that leads to membrane fusion. 39 
40 
Introduction 41 
Rift Valley fever virus (RVFV) is an emerging pathogen that affects ruminants and humans and is 42 
transmitted between susceptible hosts by different species of mosquitoes. RVFV was first isolated in 43 
Kenya in 1930, and has since spread throughout the African continent and the Arabian Peninsula (12, 44 
46). An outbreak of RVFV can have a devastating socio-economic impact on the region (2, 18, 50) and 45 
is characterized by abortion storms in adult livestock and high mortality among newborns. Humans 46 
can also be infected through contact with infected tissues or via mosquito bites, typically causing a 47 
self-limiting febrile illness. A small percentage of human infections result in hemorrhagic fever or 48 
encephalitis with generally fatal outcome (41).  49 
RVFV belongs to the Phlebovirus genus of the Bunyaviridae family, which comprises four additional 50 
genera (Orthobunyavirus, Hantavirus, Nairovirus and Tospovirus). Members of the Bunyaviridae family 51 
are enveloped viruses of ~100 nm in size that have a tripartite negative-strand RNA genome which is 52 
replicated in the cytoplasm. The genomic segments are encapsidated by the nucleocapsid protein 53 
forming the ribonucleoproteins (RNPs) (56). The lipid envelope surrounding the RNPs contains an 54 
ordered shell made up by units of two glycoproteins, Gn and Gc (20). These glycoproteins are 55 
responsible for entry into the host cell but their precise functional roles in receptor binding and fusion 56 
are poorly understood. Gn and Gc are type-I membrane glycoproteins which form heterodimers after 57 
post-translational processing of a glycoprotein precursor in the endoplasmic reticulum. By virtue of a 58 
Golgi-localization signal in Gn, the Gn-Gc heterodimers are targeted to the Golgi apparatus (56, 65). 59 
Here, interaction between the Gn carboxyl-terminal cytoplasmic tail and the RNPs allows virus 60 
budding into the lumen of the Golgi-cisternae (45, 47, 56). In the case of the RVFV virion, a 78-kDa 61 
protein consisting of pre-Gn and Gn regions has been identified as a third but minor structural 62 
component (27, 60). Cryo-electron microscopy studies of RVFV virions showed that the viral envelope 63 
comprises 720 heterodimers of Gn (54-kDa) and Gc (56-kDa), forming 110 cylinder-shaped hexamers 64 
and 12 pentamers according to a T=12 icosahedral lattice (13, 24). 65 
Enveloped viruses carry dedicated proteins in their envelope which mediate fusion between viral and 66 
cellular membranes allowing translocation of the viral genome into the cytoplasm. This membrane 67 
fusion process is driven by structural rearrangements in the metastable viral fusion protein which are 68 
triggered by either receptor binding, proteolytic cleavage or the acidic pH of endosomes allowing 69 
fusion to occur at the right time and place (8). Viral fusion proteins have been divided into three 70 
classes (class I, II and III) based on their structural features (67). The Gc glycoprotein of bunyaviruses 71 
has been proposed to be a class II viral fusion protein (15, 53). Similar to class II fusion proteins of 72 
alphaviruses and flaviviruses, Gc is predicted to be mainly composed of β-sheet structures, is 73 
synthesized from a polyprotein downstream of a companion protein (Gn) and  assembles into a 74 
heterodimer in the ER (15, 48, 62, 63). 75 
Common to all class II fusion proteins is that they utilize the low pH in the acidified endosome to 76 
activate their fusion process. Low pH triggers the dissociation of the glycoprotein dimeric state, 77 
resulting in exposure and subsequent insertion of a highly hydrophobic stretch of amino acids. 78 
Insertion of this fusion peptide into the target membrane is followed by trimerization of the monomeric 79 
fusion proteins. A stable trimeric hairpin structure is subsequently formed which brings together the 80 
fusion peptide and transmembrane domain at one end of the molecule, mediating the fusion of the 81 
cellular and viral membrane. While the acid-induced conformational changes of class II viral fusion 82 
proteins have been well documented (see for an comprehensive review (30)), the mechanism of low 83 
pH triggering is not well understood. Protonation of histidines has been suggested to act as a 84 
molecular switch that triggers the activity of pH-activated viral fusion proteins (4, 28). The rationale for 85 
this hypothesis is that histidine is the only amino acid residue with a side-chain pKa value (pKa 6.4) 86 
within the pH range found in the endo-lysosomal pathway (pH 4.5-6.5) (28, 54).  Evidence in support 87 
of a crucial role for histidine protonation in promoting fusion protein rearrangements leading to fusion 88 
has been obtained for a number of low pH-dependent viruses (3, 4, 6, 14, 26, 34, 36, 49, 57, 61).  89 
Knowledge on the fusion mechanism of bunyaviruses is still in its infancy. In agreement with a class II 90 
virus classification, bunyaviruses appear to have an acid-dependent fusion machinery. Exposure of 91 
cells overexpressing RVFV Gn and Gc to low pH results in the formation of multi-nucleated cells (11). 92 
Acid-induced syncytia formation has also been reported for other members of the Bunyaviridae family 93 
including Uukuniemi virus (UUKV, Phlebovirus genus), La Crosse virus (Orthobunyavirus genus) and 94 
Hantaan virus (Hantavirus genus) (1, 39, 42, 48). In accordance with the hypothesis of acid-induced 95 
fusion activation, bunyaviruses are sensitive to acidotropic agents which raise the pH of intracellular 96 
endocytic compartments (55, 58). In addition, acid-exposure of plasma membrane-bound UUKV could 97 
bypass the endosomal acidic pH requirement, needed for infection (39).   98 
In this study we have examined the entry mechanism of RVFV. Studies on natural RVFV strains have 99 
been hampered by the requirement of handling the virus under biosafety level-3 containment (BSL-3). 100 
We have taken advantage of our recently established nonspreading RVFV (RVFVns) production 101 
system which can be handled outside of BSL-3 (33). This system allows the efficient production of 102 
RVFV particles upon transfection of a single Gn/Gc-expression plasmid into a replicon cell line which 103 
maintains the replication machinery of RVFV. The expression of the eGFP gene from the viral genome 104 
enables infection to be easily monitored. Most importantly, the system greatly facilitates Gn and Gc 105 
structure/function studies as long as particle assembly is not compromised. Using RVFVns, we have 106 
examined the endocytic uptake of the virus, the low pH dependence and kinetics of virus entry, the 107 
effects of low pH treatment of the virus on infectivity and rearrangement of the glycoproteins as well as 108 
the role of conserved histidines in Gn and Gc in virus entry. 109 
110 
Material and methods 111 
 112 
Cells and viruses 113 
BHK cells were grown in Glasgow minimum essential medium (GMEM; Invitrogen) supplemented with 114 
4% tryptose phosphate broth, 1% minimum essential medium nonessential amino acids (MEM NEAA; 115 
Invitrogen), and 5% (v/v) fetal calf serum (FCS; Bodinco). For maintenance of BHK-Rep2 cells (33), 116 
Geneticin (G-418) was used at a concentration of 1 mg/ml. A549 and CHO K1 cells were grown in 117 
Dulbecco's Modified Eagle Media (DMEM; Lonza, Biowhittaker) and Ham's F-12K medium 118 
(Invitrogen), respectively, supplemented with 10% FCS. Cells were grown at 37°C and 5% CO2. 119 
Drosophila Schneider (S2) cells (Invitrogen) were grown at 27°C in serum-free InsectXpress medium 120 
(Lonza). Recombinant RVFV (RVFVrec) and RVFVns have both been rescued from cDNA as described 121 
(33). VSV-ΔG/GFP/G* is a recombinant vesicular stomatitis virus of which the glycoprotein gene has 122 
been replaced by that of GFP. The virus was pseudotyped with its authentic glycoprotein G as 123 
described (5). 124 
 125 
Plasmids 126 
The QuickChange XL site-directed mutagenesis kit (Stratagene) was used to exchange specific 127 
histidine for alanine codons in the pCAGGS-M expression plasmid (33) according to the 128 
manufacturer’s protocol at amino acid positions 157, 540, 572, 580, 778, 836, 857, 1087 of the RVFV 129 
M segment (GenBank:JF784387). The recombinant plasmids were sequenced to confirm that only the 130 
desired mutations were present. 131 
To generate a stable Drosophila S2 cell line expressing the Gc ectodomain (Gce) of RVFV 132 
(GenBank:JF784387), a truncated version of the Gn-Gc coding sequence lacking the transmembrane 133 
and cytoplasmic domain of Gc (GnGce; 153-AEDPHL / FGGPLK-1158) was cloned into the 134 
pMT/BiP/V5-HisA (Invitrogen) expression vector downstream of the BiP encoding signal sequence. A 135 
quadruple Strep-tag encoding sequence separated by glycine linkers 136 
(DPTGWSHPQFEK(GGGSGGGSGGGSWSHPQFEK)3) was appended C-terminally to allow 137 
purification of the secreted Gc ectodomain from the culture supernatant using Strep-Tactin sepharose 138 
affinity chromatography (IBA GmbH). Stable S2 cell lines were generated according to the 139 
manufacturer’s protocol (Invitrogen) with minor modifications. S2 cells were transfected with the 140 
expression vector and pCoBlast plasmid in a 1:19 ratio. Stable cell lines were subsequently selected 141 
at 27°C in serum-free InsectXpress medium containing 25 µg/ml Blasticidin-S-HCl (Invitrogen) and 142 
maintained in this culture medium in the presence of 10 µg/ml Blasticidin-S-HCl. 143 
 144 
Production of polyclonal antiserum against Gc ectodomain 145 
Polyclonal antibodies were raised against Gc-ectodomain after immunization of rabbits (Davids 146 
biotechnologie). Rabbits were immunized at day 0, 14 and 21 with ~40 µg of Strep-tag purified Gc-147 
ectodomain. Total serum was collected at day 35.  148 
 149 
Chemicals 150 
Bafilomycin A1, dynasore, cytochalasin D, nystatin (Sigma) and dyngo-4a (Abcam) were prepared in 151 
dimethylsulfoxide (DMSO). Chlorpromazine and ammonium chloride (Sigma) were prepared in distilled 152 
sterile water. Diethyl pyrocarbonate (DEPC, Sigma) was dissolved in 96% ethanol. 153 
 154 
Fluorescence-activated cell sorting (FACS) 155 
Flow cytometry was performed on a FACS Calibur flow cytometer (Becton Dickinson 156 
Immunocytometry Systems). For the analysis of the data, Cyflogic 1.2.1 software was used. 157 
 158 
Fluorescence microscopy 159 
Fluorescence microscopy on living or fixed cells (fixed with 3.7% formaldehyde for 20 minutes at room 160 
temperature) was performed on the EVOS fl microscope (AMG). Nuclei of fixated cells were stained 161 
with 4'-6-diamidino-2-phenylindole (DAPI). 162 
 163 
Production of RVFVns particles 164 
RVFVns particles were produced as described (33). In short, BHK-rep2 cells (33) were seeded in 165 
Optimem medium (Invitrogen) supplemented with 2% FCS. Cells were transfected (JetPEI, Polyplus) 166 
with pCAGGS-M (or derivatives thereof) in Optimem containing 0.2% FCS. Twenty hours post 167 
transfection the RVFVns particles in the collected medium were concentrated and transferred into a 168 
phosphate buffered saline (PBS) or HNE pH 7.4 buffer (5mM HEPES, 150mM NaCl, 0.1mM EDTA) 169 
using Amicon® Ultra centrifugal filters (Millipore) with a molecular weight cut-off of 100,000 kilodalton 170 
(Millipore). Titers of RVFVns stocks were determined by TCID50 analysis as described (33). 171 
 172 
Inhibition of RVFV infection by pharmacological drugs 173 
To analyze the effects of specific drugs on RVFV entry, BHK-21 cells were pre-treated for one hour 174 
with ammonium chloride, chlorpromazine (both dissolved in water), bafilomycin A1, cytochalasin D, 175 
dynasore, dyngo-4a or nystatin (the latter four dissolved in DMSO). Cells were inoculated for two 176 
hours with RVFVns or VSVns (moi ~0.4) at 37°C, before the culture medium was replaced by medium 177 
containing 10 or 40 nM bafilomycin A1, respectively. Cells were further incubated at 37°C. Inhibitory 178 
effects of the compounds on virus replication were tested by addition of the chemicals two hours post 179 
infection (hpi). After a period of three hours the drug containing medium was replaced by culture 180 
medium containing bafilomycin (10 nM). RVFVns or VSVns infection was quantified at 20 or 8 hours 181 
after virus inoculation, respectively, by analysis of GFP-expressing cells using FACS or fluorescence 182 
microscopy. Viability of the drug-treated cells was measured using a WST-1 assay (Roche) according 183 
to manufacturers’ recommendations. 184 
 185 
Ammonium chloride add-in time course  186 
Infection was synchronized by allowing RVFVns particles to bind to cells on ice for 1 h in serum free 187 
medium. The cells were washed with cold medium to remove unbound virus and subsequently 188 
transferred rapidly to a 37°C water bath after addition of serum free pre-warmed Roswell Park 189 
Memorial Institute 1640 medium (RPMI-1640, Invitrogen) adjusted at different pHs. Ammonium 190 
chloride (10 mM) was added to the medium at indicated times. Infection (GFP-positive cells) was 191 
quantified at 18 hours post warming by FACS and fluorescence microscopy.  192 
 193 
Polyacrylamide gel electrophoresis (PAGE), Western blotting and dot-blot analysis 194 
Samples containing RVFVns particles were heated for 10 minutes at 40-80°C in Laemmli sample buffer 195 
lacking β-mercaptoethanol (LSB-) and loaded onto NuPAGE® bis-tris gels (Invitrogen). After 196 
separation, proteins were blotted onto polyvinylidene fluoride (PVDF) membranes. Western blot 197 
analysis was performed using a rabbit Gc peptide antiserum (9), a rabbit polyclonal serum against Gce 198 
(see above), the 4-D4 mouse αGn monoclonal antibody (provided by Dr. Connie Schmaljohn, 199 
USAMRIID) (29) or a sheep polyclonal antiserum against RVFV (32) as the primary antibody and an 200 
appropriate peroxidase-conjugated secondary antibody. For dot blot analysis, samples containing 201 
RVFVns particles were heated for 20 minutes at 80°C and spotted onto nitrocellulose membrane 202 
(Whatmann). The membrane was blocked with PBS containing 0,05% Tween20 (v/v) and 5% protifar 203 
(w/v, Nutricia). RVFVns particles were detected using the 4-D4 αGn monoclonal antibody.  204 
 205 
Fusion at the plasma membrane  206 
RVFVns particles were allowed to bind to a confluent layer of BHK-21 cells on ice for 2 hours. Cell-207 
bound virus was subsequently exposed to pre-warmed RPMI-1640 medium for 3 minutes at 37°C 208 
(water bath). The pH of the culture medium varied from pH 7.4 to 5.0. The RPMI medium was 209 
replaced by culture medium containing bafilomycin A1 (20nM) and cells were further incubated at 210 
37°C, 5% CO2. Twenty hours after the 3 minute pH-shock, infection (GFP-positive cells) was 211 
quantified by FACS and fluorescence microscopy.  212 
 213 
Low pH treatment of RVFVns particles 214 
RVFVns particles in HNE buffer pH 7.4 were exposed to conditions ranging from pH 7.4 to 5.0 by 215 
addition of a pre-titrated volume of 100mM MES (pH 6.5 to 5.3) or 200mM HAc (pH 5.0). The particles 216 
were incubated for 3 minutes at the desired pH at 37°C before the samples were back-neutralized to 217 
pH 7.4 with 0.1N NaOH. Samples were subsequently used to infect BHK-21 cells and infection was 218 
analyzed 20 hpi by FACS and fluorescence microscopy. To analyze the effect of low pH treatment on 219 
the structural glycoproteins Gn and Gc, the pH of HNE buffered RVFVns particles was varied from pH 220 
7.4 to 4.25 by addition of MES (pH 6.5 to 5.3), 200mM HAc (pH 5.0 to 4.75) or 500mM HAc (pH 4.5 to 221 
4.25). The RVFVns particles were incubated for 0-10 minutes at 37°C and the buffer was subsequently 222 
returned to pH 7.4 by adding a predetermined amount of 0.1N NaOH or 0.5N NaOH (pH 4.25). 223 
Samples were analyzed by Western blotting as described. 224 
 225 
DEPC treatment of RVFVns particles 226 
A  diethylpyrocarbonate (DEPC) solution (1M) in 96% ethanol was freshly prepared from a 1.12 g/ml 227 
commercial stock (Sigma). RVFVns particles in PBS were incubated with indicated concentrations of 228 
DEPC for 10 minutes at 37°C. BHK-21 cells were inoculated with the treated virus for 20 hours and 229 
assayed for infection (GFP-positive cells) by FACS and fluorescence microscopy.  230 
 231 
Statistics 232 
The data are representative of multiple independent experiments. Values are shown as mean values ± 233 
standard deviation (SD). Standard deviations were calculated using GraphPad Prism version 5.00 for 234 
Windows (GraphPad Software). 235 
  236 
Results 237 
 238 
Entry of RVFV by endocytic uptake 239 
We started our studies on RVFV cell entry with a limited pharmacological drug screen to investigate 240 
the uptake of the virus into cells using established inhibitors of cellular endocytic pathways. BHK-21 241 
cells were pre-treated for one hour with different concentrations of drugs that interfere with dynamin-2 242 
(dynasore), caveolin- (nystatin), clathrin- (chlorpromazine) or actin- (cytochalasin D) dependent 243 
endocytosis. Cells were then inoculated with nonspreading RVFV (RVFVns) at a moi of ~0.4 in the 244 
presence of the drugs and subsequently incubated without the drugs but in the presence of 245 
bafilomycin A1 to inhibit further infection (Fig. 1A). A nonspreading recombinant of VSV (VSVΔG-246 
GFP/G*, in short VSVns) was taken along as a control virus (5). Both viruses express GFP from the 247 
viral genome facilitating quantification of infection. Treatment of BHK-21 cells with dynasore or 248 
chlorpromazine, but not with the other compounds tested, reduced RVFV infection considerably, 249 
stronger even than they affected VSV infection, which is well known to be dependent on dynamin-2 250 
and clathrin during entry (Fig. 1A). The presence of these drugs did not have a significant effect on the 251 
cell viability (Fig. 1B). Importantly, infection of RVFVns was hardly affected if dynasore or 252 
chlorpromazine was added two hours post inoculation, indicating that the drugs only affect the entry 253 
stage of infection (Fig 1C). Similar effects of dynasore and chlorpromazine on RVFVns infection were 254 
seen on A549 cells (data not shown). We confirmed the involvement of dynamin-2 in RVFVns entry on 255 
BHK-21 cells using a novel and potent inhibitor of dynamin-2 named dyngo-4a (23) (Fig. 1B and Fig. 256 
1D). Dynasore and chlorpromazine also strongly inhibited entry of a recombinant RVFVrec expressing 257 
GFP (Fig 1E). These drug inhibition data indicate that entry of RVFV is sensitive to inhibitors which 258 
interfere with dynamin-2 and clathrin-dependent endocytosis. 259 
 260 
RVFV entry depends on vacuolar acidification 261 
Previously it was described that low pH incubation of cells overexpressing the RVFV glycoproteins  262 
resulted in extensive cell-cell fusion, suggesting that after endocytosis RVFV fusion is activated by the 263 
acidic environment of endosomal compartments (11, 37). To explore the requirements of a low 264 
endosomal pH for virus entry we analyzed the infection of RVFVns in the presence of the 265 
lysosomotropic agents bafilomycin A1, an inhibitor of vacuolar-type H+-ATPase proton pumps, and the 266 
lipophilic weak base ammonium chloride (NH4Cl), which both prevent acidification of endosomal 267 
compartments. VSVns, known to be acid-activated in early endosomes with a pH threshold of pH 6.1 268 
(35, 68), was used as a control. The results demonstrate that RVFVns entry is strictly dependent on 269 
vacuolar acidification as infection of BHK-21 and A549 cells was inhibited by bafilomycin A1 as well as 270 
by NH4Cl (Fig. 2A). Compared to VSVns, RVFVns appears to be more sensitive to the lysosomotropic 271 
agents suggesting that the virus has a lower pH threshold for activation and therefore may be 272 
activated in more acidic vacuoles beyond the early endosomal compartments.  273 
To define the time of acid exposure after receptor binding we used a previously described NH4Cl add-274 
in experiment (40). Addition of NH4Cl to the medium is known to almost instantly raise the endosomal 275 
pH (43) allowing studies on the kinetics by which viruses pass the acid-requiring entry step after 276 
binding. We synchronized the infection of RVFVns by allowing the virus to bind to cells in the cold. After 277 
removal of the unbound virus, we rapidly transferred the cells to 37°C and added 10mM NH4Cl at 278 
different times post warming. About ninety percent of the virus experienced the acid-requiring step 279 
between 4 to 48 minutes after warming of the cells (Fig. 2B).  The entry kinetics of RVFVns are similar 280 
to those reported for the Phlebovirus UUKV (39) and influenza viruses (40), which were both shown to 281 
fuse at low pH in late endosomal or lysosomal compartments (38, 39, 69). 282 
  283 
RVFV fusion occurs at acidic conditions that resemble the endo-lysosomal compartments                                   284 
To determine the pH threshold for fusion of RVFV we measured infection after low-pH induced fusion 285 
at the plasma membrane under conditions where acidification of endosomes - and normal virus entry - 286 
is blocked by bafilomycin A1. In this acid-mediated endocytosis bypass experiment, that was 287 
previously described for SFV and UUKV (19, 39), RVFVns particles were bound to cells in the cold and 288 
subsequently exposed for 3 minutes at 37˚C to media with varying pH. Medium was replaced with 289 
culture medium containing bafilomycin A1 to inhibit further infection via the endocytic pathway. The 290 
results demonstrate that treatment of the cell-bound virus at or below pH 5.5 fully bypassed the 291 
requirement for vacuolar acidification (Fig. 3A). The bypass was less efficient at pH 5.7 and only 292 
limited infection was observed at pH 6 or higher, indicating that the pH threshold for RVFV membrane 293 
fusion is around pH 5.7. Exposure of free RVFVns particles to low pH (pH 6.5 - 5) for 3 minutes did 294 
reduce virus infectivity, although virus inactivation was not complete (Fig. 3B). 295 
 296 
Acid induced rearrangement of the Gc into higher-order structures  297 
Next we examined the effects of exposure to low pH on the structural organization of the RVFV 298 
envelope glycoproteins. RVFVns particles were incubated in buffers of low pH for 10 minutes. After 299 
neutralization of the buffers, viral proteins were analyzed by Western blotting performed under non-300 
reducing conditions. The Gn and Gc glycoproteins as well as the 78-kDa protein were detected using 301 
a polyclonal RVFV serum, a Gn-specific monoclonal antibody and with a Gc-specific peptide serum 302 
(Fig. 4A). Incubation of RVFVns at the low pH conditions that activate virus entry (pH<6; Fig. 3A) led to 303 
the disappearance of the Gc monomer and the concomitant appearance of a more slowly migrating 304 
protein moiety. Incubation at low pH did not influence migration of the Gn or the 78k-Da protein. The 305 
disappearance of the Gc monomer suggested that the slowly migrating band consists of an oligomer 306 
of Gc, which can be detected by the polyclonal RVFV serum but, perhaps through epitope 307 
inaccessibility, not by the Gc peptide serum. Consistent with this notion, heating of acid-activated 308 
RVFVns to 90°C resulted in the disappearance of the slowly migrating band and the simultaneous 309 
appearance of monomeric Gc (Fig. 4B). To further study the identity of the presumed Gc oligomer we 310 
produced a polyclonal antiserum by inoculating rabbits with the ectodomain of Gc produced using the 311 
Drosophila expression system. This antiserum efficiently recognized the monomeric as well as the 312 
slower migrating form of Gc on Western blots confirming the identity of the Gc oligomer (Fig. 4C). 313 
Using this antiserum, we analyzed the kinetics of Gc oligomer formation. The conversion of Gc into 314 
SDS-stable oligomers slowly increased with time of pH treatment (Fig. 4C). Conversion became 315 
detectable already after 15 seconds and was nearly complete after 4 minutes of incubation at low pH. 316 
These results demonstrate that incubation of RVFV at the fusion-activating pH triggers a structural 317 
reorganization of Gc from an apparently metastable to a highly stable oligomeric conformation, 318 
reminiscent of the stable acid-activated trimeric class II fusion proteins of alpha- and flaviviruses (31, 319 
59, 64). 320 
 321 
RVFV entry is inhibited by substitution of a single histidine in Gc 322 
Protonation of one or more histidines can be crucial for triggering conformational changes in viral 323 
fusion proteins (28). A first clue for a ´pH sensing´ role of histidines in RVFV infection came from the 324 
observation that pre-incubation of RVFVns with diethylpyrocarbonate (DEPC), a chemical which 325 
specifically modifies the aromatic ring of histidines preventing its protonation (7), clearly inhibits RVFV 326 
infection of BHK-21 cells in a concentration dependent manner (Fig. 5A). To further study the role of 327 
histidine protonation in entry, we identified and replaced eight conserved histidines in Gn and Gc 328 
(Table 1 and Fig. 5B) by the small and non-polar amino acid alanine. RVFVns particles carrying the 329 
histidine-to-alanine replacements were produced and secreted from BHK-21 replicon cells (33) with 330 
efficiencies resembling that of wild-type RVFVns, indicating that the mutations in Gn and Gc did not 331 
impair assembly and release of virus particles (data not shown). Amounts of mutant and wildtype virus 332 
particles were normalized using a dot blot assay and equal virus quantities were compared for their 333 
relative infectivity’s (Fig. 5C). RVFVns mutants with histidine-to-alanine substitutions in Gn were all 334 
viable although their infectivity was slightly reduced. In contrast, three of the four histidine-to-alanine 335 
substitutions in Gc either completely abolished (mutant H857A) or strongly impaired infectivity 336 
(mutants H778A and H1087A) to less than 5% relative to that of wild-type RVFVns.  337 
 338 
H857 is essential for acid-induced rearrangement of Gc into higher order structures 339 
Next we analyzed the effects of the histidine-to-alanine mutations on the formation, stability and 340 
conversion kinetics of the Gc oligomer. Acid exposure of similar amounts of mutant and wildtype 341 
RVFVns particles resulted in the formation of the SDS-resistant Gc oligomer in all mutants, with the 342 
exception of mutant H857A (Fig. 6A, upper left panel). The Gc oligomers of mutants H778A, H836A 343 
and H1087A were not stable at 80°C in contrast to wildtype and the Gn histidine mutants (Fig. 6A, 344 
lower left panel). To analyze their thermostability in more detail, the Gc oligomers were subjected to 345 
heating at different temperatures prior to Western blot analysis. Compared to wildtype, the Gc 346 
oligomer of the H778A, H836A and H1087A mutants appeared slightly less thermostable and 347 
dissociated at 80°C but not at 70°C (Fig. 6A, right panels). Next, we assessed the effects of the 348 
mutations on the Gc conversion kinetics into the SDS-stable oligomer upon acid exposure, by Western 349 
blotting (Fig. 6B). Conversion kinetics of the Gc mutants H778A, H836A and H1087A upon pH 350 
treatment appeared grossly similar to that of wildtype (Fig. 6B). Clearly, acid exposure even up to 30 351 
minutes of the Gc mutant carrying the lethal H857A substitution did not allow the formation of the 352 
SDS-resistant Gc oligomer (Fig. 6B) suggesting that the formation of the stable Gc oligomer induced 353 
by protonation of histidine 857, is essential for virus entry into the host cell. Finally, to assess a 354 
possible shift in the pH activation threshold, we analyzed the Gc conversion for the H857A Gc mutant 355 
and wildtype RVFVns particles at pH values below pH 5.5. Incubation at these acidic conditions for 10 356 
minutes at 37ºC resulted in the formation of the stable oligomer in wildtype RVFVns particles. In 357 
contrast, no stable Gc oligomer was observed after treatment of RVFVns particles containing the 358 
H857A mutation (Fig. 6C). 359 
Discussion 360 
 It is well established that bunyaviruses require the acidic pH found in endosomes to activate fusion, 361 
but it remains unclear how fusion is mediated at the molecular level. In this study we demonstrate that 362 
exposure of RVFV particles to acidic pH converts the viral Gc protein into a highly stable oligomer. The 363 
pH required for this major conformational change correlates with the pH threshold required to activate 364 
fusion of virus particles at the plasma membrane. Mutagenesis of conserved histidines in the viral 365 
glycoproteins identified a single histidine in Gc that was strictly required for entry as well as for the 366 
acid-induced conversion of Gc into its stable oligomeric form. These data provide new insight into the 367 
molecular basis of bunyavirus acid-activated fusion.  368 
Most bunyaviruses studied to date utilize clathrin mediated endocytosis to gain access to the cell 369 
interior (22, 25, 38, 39, 55, 58). For UUKV a clathrin-independent pathway has been suggested as an 370 
alternative route (39). We demonstrate here that RVFV entry is sensitive to drugs perturbing the 371 
function of clathrin and dynamin, which is consistent with entry via a clathrin-mediated endocytic 372 
pathway. Further studies are required to confirm this assumption. Upon endocytosis, RVFV particles 373 
are transported deep into the cell through maturing endosomes. The pH threshold (pH<6) required for 374 
virus fusion at the plasma membrane and rearrangement of Gc suggests that fusion of RVFV occurs in 375 
late endosomes. This late penetration is consistent with the half-time of RVFV of ~20 minutes during 376 
which the virus undergoes its acid-activating step. Similar pH thresholds and penetration kinetics have 377 
been observed for UUKV, another Phlebovirus (39). Our data indicate that RVFV can be classified as 378 
a late-penetrating virus (38). 379 
Exposure to low pH converts the RVFVns Gc protein from an apparently metastable to a highly stable 380 
oligomeric conformation. Similar pH-induced rearrangements have been reported for envelope 381 
glycoproteins of other bunyaviruses. These conformational changes have been shown to either lead to 382 
dissociation of the Gn-Gc heterodimer (Hantavirus), to changes in the Gc antigenic structure or to 383 
alteration in the cleavage pattern after proteolytic processing of the Gc protein (UUKV, La Crosse) (16, 384 
21, 52). The low pH-induced changes in the glycoprotein shell of UUKV virions have been visualized 385 
nicely by electron microscopy, revealing the flattening of the glycoprotein capsomers (44, 52). Low pH 386 
incubation of La Crosse virus and UUKV leads to virus aggregation (44, 66). Activation of fusion 387 
proteins generally triggers the exposure of a hydrophobic ‘fusion peptide’ which normally functions by 388 
inserting into the host membrane and initiating fusion which might explain the observed acid-induced 389 
virus aggregation. Typically, fusion proteins are trimeric in this fusion active state (8, 17). Hence we 390 
assume that the RVFV Gc stable oligomer is also made up of three Gc molecules, but further research 391 
is needed to confirm this hypothesis.  392 
The acid-induced Gc oligomer displays a remarkable resistance to temperature dissociation and SDS-393 
detergent denaturation (10). In agreement with these observations back-neutralization of the acid-394 
exposed virus particles did not reverse the transition of Gc into a stable oligomer. In general, viral 395 
fusion proteins convert to a stable form during fusion thereby generating the energy needed for 396 
membrane coalescence. For class I and II viral fusion proteins this transition was shown to be 397 
irreversible (51). Intriguingly, exposure of virus to the activating pH in the absence of target 398 
membranes also fully converts Gc into the stable oligomer; yet, although a reduction is seen, it does 399 
not completely inactivate virus infectivity, not even after incubation times of up to 16 minutes (data not 400 
shown). It remains to be seen whether the stable Gc oligomer represents the final post-fusion form of 401 
the Gc fusion protein or represents a crucial intermediate which awaits further reorganization. In the 402 
latter situation alternative factors (e.g. interaction with the target membrane) may be required to drive 403 
the conformational rearrangements to completion. 404 
In the RVFV virion, Gc is organized as a heterodimer together with Gn (24). The Gn-Gc heterodimer is 405 
the building block of 110 hexamers and 12 pentamers containing six and five of the Gn-Gc 406 
heterodimeric units, respectively. Together these 122 capsomers make up the icosahedral shell of the 407 
virion following a T=12 triangulation (13, 24). Exposure of virions to the activating pH will lead to 408 
rearrangement of the metastable Gn-Gc heterodimer and concomitantly enforces the interactions 409 
between Gc subunits resulting in the formation of a Gc homo-oligomer. Exposure of virions to the 410 
acidic pH of 6 did not have any impact on the structure of RVFV particles, as shown by cryo-electron 411 
tomography, consistent with the fusion activating pH threshold of below 6 that we observed (24). It will 412 
be interesting to investigate how the Gc protomers in the virions - organized as pentamers and 413 
hexameric Gn-Gc heterodimers - collectively undergo the structural transition towards the 414 
(presumably) trimeric Gc oligomer after exposure to the activating pH.  415 
Protonation of histidines in Gc may play a key role at different stages of the fusion process. The 416 
inability of the H857A mutant to form stable Gc oligomers in combination with its abrogated entry 417 
function suggests that Gc oligomerization is essential for virus entry and that protonation of H857 418 
plays a crucial role in this process. In addition, the substitution of H778 and H1087 in Gc has a severe 419 
effect on virus entry, yet Gc oligomerization still occurred and the temperature stability was only 420 
marginally affected. This suggests that formation of the Gc oligomer, although required, may not be 421 
sufficient for inducing fusion. We speculate that the single mutations may impair a later step in the 422 
fusion reaction (36). The H778, H857 and H1087 histidines in Gc may collectively contribute to pH 423 
sensing, initiation and propagation of conformational rearrangements towards the post-fusion 424 
structure. Further interpretation of the consequences of the histidine substitutions awaits the 425 
elucidation of the high-resolution structures of the Gc protein in its pre- and postfusion state. 426 
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 584 
 FIG 1 Rift Valley fever virus enters the cell via endocytosis. (A) BHK-21 cells were pre-treated for 1 585 
hour with two-fold dilutions of the indicated drugs and inoculated with RVFVns (moi~0.1) or VSVns 586 
(moi~0.8) for 2 hours in the continued presence of the drugs after which the inoculum was replaced by 587 
culture medium containing bafilomycin A1 (10-40 nM) to inhibit further RVFV entry (see Fig.2). 588 
Infection was quantified 20 hours (RVFVns) or 8 hours (VSVns) post infection by measuring GFP-589 
positive cells using FACS. The data are the means of three independent experiments done in 590 
duplicate. ND; no drugs, SO; solvent (1% DMSO), dyn; dynasore, nys; nystatin, cyt; cytochalasin D, 591 
chl; chlorpromazine. (B) BHK-21 cells were incubated with the indicated drugs for three hours after 592 
which medium containing the drugs was replaced for culture medium containing bafilomycin A1 (20 593 
nM). Twenty hours later, the effect of the chemical compounds on the metabolic activity of the cells 594 
was determined using a spectrophotometric assay. Cells were considered viable if the relative 595 
metabolic activity of treated cells remained above 70% (indicated by the dashed line) relative to 596 
untreated cells (ND). The results shown are representative of two independent experiments performed 597 
in triplicate. dgo; dyngo-4a. (C) BHK-21 cells were infected with RVFVns (moi~0.2) for 2 hours after 598 
which infection was continued for three hours in the presence of 80 or 40 µM dynasore or 20 or 40 µM 599 
chlorpromazine. Cells were incubated overnight in culture medium containing bafilomycin A1 (20 nM). 600 
At twenty hours post infection, infected (GFP-positive) cells were quantified by FACS. Data shown are 601 
representative of two independent experiments performed in duplicate. NI; not infected. (D) Analysis of 602 
the effect of dyngo-4a on RVFVns and VSVns infection (moi ~0.4) of BHK-21 cells. Infection was 603 
performed and quantified as described under (A). (E) Representative fluorescence pictures of BHK-21 604 
cells infected with RVFVns or RVFVrec in the presence of dynasore (80μM) or chlorpromazine (40μM). 605 
Infection was performed as described under (A) at a moi of ~0.2. Nuclei were stained with DAPI. 606 
Pictures are representative of two independent experiments performed in duplicate. 607 
 Fig 2 Entry of RVFVns depends on vacuolar acidification. (A) BHK-21 or A549 cells were pre-treated 608 
for 1 hour with different concentrations of bafilomycin A1 or ammonium chloride (NH4Cl) and 609 
subsequently infected with RVFVns (moi~0.1) or VSVns (moi~0.8). Infection (GFP-positive cells) was 610 
quantified by FACS. Results shown are representatives of three individual experiments performed in 611 
duplicate. NI; not infected, ND; no drugs. (B) RVFVns was bound to BHK-21 cells for 1 hour in the cold 612 
and subsequently warmed to 37°C. NH4Cl (10mM) was added at indicated times to instantly raise the 613 
endosomal pH thereby inhibiting further infection. Eighteen hours post warming, infection (GFP-614 
positive cells) was analyzed by fluorescence microscopy and quantified by FACS. Untreated cells 615 
yielded ~70% infection. Graphical data shown are representative of two independent experiments 616 
performed in duplicate. NI; not infected, ND; no drugs, C; NH4Cl control (not infected). 617 
 FIG 3 Low pH-activated penetration of cell-bound RVFVns and inactivation of unbound RVFVns 618 
particles. (A) RVFVns was allowed to bind in the cold to a confluent monolayer of BHK-21 cells for 2 h 619 
before the cell-bound virus was exposed for 3 minutes at 37°C at the indicated pH. Infection was 620 
continued in culture medium containing bafilomycin A1 (20 nM) to inhibit infection via the endocytic 621 
route. Infection (GFP-positive cells) was analyzed 20 hours post warming by fluorescence microscopy 622 
and was quantified by FACS. Untreated cells (pH 7.4) yielded ~40% infection. The results shown are 623 
representative of two individual experiments performed in triplicate. (B) RVFVns particles were 624 
incubated at the indicated pH for 3 minutes at 37°C. After neutralization of the medium infectivity of the 625 
virus was assayed on BHK-21 cells. Infection (GFP-positive cells) was analyzed 20 hours post 626 
infection by fluorescence microscopy and quantified by FACS. Virus incubated at neutral pH resulted 627 
in ~30% GFP positive cells. Graphical data shown are representative of four individual experiments 628 
performed in duplicate. The control in A and B represent cells that are not infected (NI). 629 
FIG 4 Acid exposure triggers the formation of a SDS- and temperature-resistant Gc oligomer. (A) 630 
RVFVns particles were exposed to the indicated pH for 10 minutes at 37ºC, returned to neutral pH and 631 
subsequently analyzed by Western blotting performed under non-reducing conditions. RVFV 632 
glycoproteins were detected with a RVFV serum, a monoclonal antibody against Gn or a polyclonal Gc 633 
peptide serum. In some cases Gc migrates as a closely spaced doublet. (B) RVFVns particles were 634 
exposed for 10 minutes to pH 5.5 at 37ºC, returned to neutral pH and heated for 20 minutes at the 635 
indicated temperatures. Samples were subsequently analyzed by Western blotting (non-reducing 636 
conditions) using a RVFV serum or a Gc peptide serum. (C) RVFVns particles were exposed to pH 5.5 637 
at 37ºC for the indicated times and analyzed by Western blotting (non-reducing conditions) using a 638 
polyclonal serum raised against the purified Gc ectodomain (Gce). OC; oligomeric complex, NC; 639 
negative control (medium from mock-transfected replicon cells), RT; room temperature. 640 
FIG 5 Role of histidines in RVFVns infectivity. (A) RVFVns was pre-treated with different concentrations 641 
of DEPC for ten minutes at 37ºC and subsequently assayed for infectivity. Infectivity (GFP-positive 642 
cells) was analyzed 20 hours post inoculation by fluorescence microscopy and quantified by FACS. 643 
BHK-21 cells inoculated with 0μM DEPC treated virus yielded ~20% infection. Graphical data shown 644 
are representative of two independent experiments performed in triplicate. SC; solvent control (0.2% 645 
ethanol). (B) Membrane topology of the RVFV M-segment encoding polyprotein starting from the 646 
fourth methionine (adapted from (16)). The predicted N-linked glycosylation sites (Y symbols) and 647 
signal peptidase cleavage sites (scissors) are indicated. The luminal domain of Gn and Gc and the 648 
cytoplasmic domains of Gn and Gc are colored in blue, green, grey and pink, respectively. The orange 649 
blocks represent the transmembrane spanning regions. The position and amino acid numbering of 650 
conserved histidines (H), calculated from the first methionine (JF784387), are indicated in the linear 651 
diagram of the GnGc polyprotein. (C) Equal amounts of wildtype and mutant RVFVns containing 652 
histidine-to-alanine substitutions determined by a dot blot assay (two-fold dilutions of viruses are 653 
shown) were analyzed for their infectivity on BHK-21 cells. BHK-21 cells inoculated with wildtype 654 
RVFVns particles resulted in ~20% infection. Infection (GFP-positive cells) was quantified by FACS. 655 
Non-infected (NI) BHK-21 cells were included as a negative control. The data shown represent the 656 
combined results of three independently produced batches of wildtype and mutant RVFVns particles 657 
tested in independent experiments, each performed in triplicate. 658 
 FIG 6 Effects of histidine substitutions in RVFV glycoproteins on the formation and stability of the Gc 659 
oligomer. (A) Equal amounts of wildtype and mutant RVFVns particles were exposed for 10 minutes to 660 
pH 5.5 at 37ºC, returned to neutral pH, heated for 20 minutes at the indicated temperatures and 661 
subsequently analyzed by Western blotting (non-reducing conditions) using a polyclonal serum raised 662 
against the Gc ectodomain (Gce). In some cases Gc runs as a closely spaced doublet. The 663 
thermostability of the acid-induced Gc oligomer is indicated for the wildtype and Gn- and Gc-His 664 
mutant RVFVns particles at 20°C and 80°C (left panel) or for the wildtype and the Gc-His mutant 665 
RVFVns particles at 40°C, 70°C and 80°C (right panel). (B) Equal amounts of wildtype and mutant 666 
RVFVns particles containing histidine-to-alanine mutations in Gc were exposed to pH 5.5 at 37ºC for 667 
the indicated times and analyzed by Western blotting (non-reducing conditions) using a polyclonal 668 
serum raised against the Gc ectodomain. OC represents the oligomeric complex, WT; wildtype. (C) 669 
Equal amounts of wildtype and H857A mutant RVFVns particles were exposed for 10 minutes at 37ºC 670 
at the indicated pH. The Gc conversion was analyzed by Western blotting as described under B. 671 
Table 1. Conservation of the selected histidines in the RVFV Gn and Gc glycoproteins among members of 
the Phlebovirus genus of the Bunyaviridae family as determined by ClustalW alignment. 
Phlebovirus Strains  
(GenBank accession number) 



































RVFV (JF784387) H H H H H H H H
SFNV (YP089671) H H H H H H H H
TOSV (AB385175) H H H H H H H H
MASV (AC1240II) H H H H H H H H
Echarte virus (HM119411) H Y Y H H H H H
TUAV (HM119432) H H N H H H H H
CDUV (HM119408) H H N H H H H H
MCRV (HM119420) H H Q H H H H H
ARQV (HM119405) H H S H H H H H
MRMBV (HM119423) H H T H H H H H
ALEV (HM119414) H H K H H H H H
ITAV (HM119417) H H K H H H H H
SRNV (HM119429) H Y K H H H H H
NIQV (HM119426) H H N H H H H H
ORXV (HM119435) H Y H H H H H H
JCNV (HM466935) H Y Y H H H H H
SFSV (AAA75043 H H E H R H H H
PTV (ABD92923) H H H H H H H H
SFTSV (HM745931) - ** H E Y R R P S
UUKV (AAA79512) - ** R A F H R Y H
*   Amino acid (AA) numbers correspond to the RVFV M-segment encoding polyprotein.                     
** ClustalW alignment displays a gap at this position   
 
 
 






